Description

Buy Fasoracetam 

(Fasoracetam bulk powder)

Fasoracetam (NS-105, LAM 105) was originally created and manufactured by a Japanese pharmaceutical company. This was primarily created to treat individuals suffering from Alzheimer’s disease. Recently however, it is being investigated for its ability to treat attention deficit hyperactivity disorder (ADHD). Some studies have shown that it has positive effects towards dementia, cognition and learning. Observation studies alongside anecdotal evidence from online reviews have also shown that fasoracetam has anxiolytic properties as well. Other than promoting general intelligence and treating anxiety symptoms, this nootropic agent have shown other cognitive benefits that includes decrease on apathetical tendencies. Fasoracetam is currently being researched for efficacy in attention deficit hyperactivity disorder. It also may help to improve depression and anxiety. Typical Fasoracetam dosage is 10-20mg.

Mechanism of Action

Fasoracetam works by modifying receptors in the brain. It interactswith the cholinergic, GABA, and glutamate receptors, which all play a role in forming and storing new memories. Like most nootropic compounds and fellow racetams, Fasoracetam affects the brain to bring about mild cognitive benefits. Users buy Fasoracetam for its benefits:

Benefits:

Anecdotal evidence and research suggests that Fasoracetam powder can improve memory and focus, relieve depression and anxiety, and even help beat procrastination by increasing motivation and mental clarity. Users that buy Fasoracetam Powder report being able to get more done, learn more efficiently, and maintain a state of calm while feeling energized.

Fasoracetam dosage: 10-20mg

CAS: 11095-19-5

Formula: C₁₀H₁₆N₂O₂

Mass: 196.246 Da

Synonyms: NS-105, LAM 105

Half-life: 4-6,5h

Bioavailability: 80-100%

References:

1.  A novel cognition enhancer NS-105 modulates adenylate cyclase activity through metabotropic glutamate receptors in primary neuronal culture.

2. Role of metabotropic glutamate receptor subclasses in modulation of adenylyl cyclase activity by a nootropic NS-105.

3. Pharmacokinetics of NS-105, a novel cognition enhancer. 2nd communication: distribution and transfer into fetus and milk after single administration, and effects of repeated administration on pharmacokinetics and hepatic drug-metabolizing enzyme activities in rats.

4. Comparison of pharmacokinetics of NS-105, a novel agent for cerebrovascular disease, in elderly and young subjects.

5. Involvement of cholinergic and GABAergic systems in the reversal of memory disruption by NS-105, a cognition enhancer.